Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT NOW
NCT00220961Phase 3Completed
- Sponsor
- UT Health San Antonio
- Start
- Jan 2004
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Pioglitazone with Placebo (2 arms). Primary endpoint: Prevention of Type 2 Diabetes at 2.4 years. Started Jan 2004; status: completed.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00220961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220961.